Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for TFRC returned no results
Showing 2101 to 2150 of 2490 results for term

  1. Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (TA536)

    Evidence-based recommendations on alectinib (Alecensa) for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer in adults.

  2. Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over (TA1054)

    Evidence-based recommendations on ruxolitinib (Jakavi) for treating acute graft versus host disease that has an inadequate response to corticosteroids in people 12 years and over.

  3. Mega Soft Patient Return Electrode for use during monopolar electrosurgery (HTG290)

    Evidence-based recommendations on Mega Soft Patient Return Electrode for use during monopolar electrosurgery.

  4. Cough (acute): antimicrobial prescribing (NG120)

    This guideline sets out an antimicrobial prescribing strategy for acute cough associated with an upper respiratory tract infection or acute bronchitis in adults, young people and children. It aims to limit antibiotic use and reduce antibiotic resistance.

  5. Nalmefene for reducing alcohol consumption in people with alcohol dependence (TA325)

    Evidence-based recommendations on nalmefene (Selincro) for reducing alcohol consumption in adults with alcohol dependence.

  6. Chief executive's end of year message

    Dr Sam Roberts, chief executive at NICE, looks back at NICE's achievements over the past year and discusses our priorities for 2023.

  7. TopClosure Tension Relief System for wound closure (MIB97)

    NICE has developed a medtech innovation briefing (MIB) on TopClosure Tension Relief System for wound closure .

  8. Obsessive-compulsive disorder and body dysmorphic disorder: treatment (CG31)

    This guideline covers recognising, assessing, diagnosing and treating obsessive-compulsive disorder and body dysmorphic disorder in adults, young people and children (aged 8 years and older). It aims to improve the diagnosis and treatment of obsessive-compulsive disorder and body dysmorphic disorder. It includes recommendations on how families and carers may be able to support people with either of these conditions, and how they can get support for themselves.

  9. High-sensitivity troponin tests for the early rule out of NSTEMI (HTG552)

    Evidence-based recommendations on high-sensitivity troponin tests for the early rule out of NSTEMI (non-ST-segment elevation myocardial infarction).

  10. Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA725)

    Evidence-based recommendations on abemaciclib (Verzenios) with fulvestrant for hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy in adults.

  11. Vedolizumab for treating moderately to severely active ulcerative colitis (TA342)

    Evidence-based recommendations on vedolizumab (Entyvio) for treating moderate to severe ulcerative colitis in adults.

  12. Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer (TA395)

    Evidence-based recommendations on ceritinib (Zykadia) for treating advanced anaplastic lymphoma kinase positive non-small-cell lung cancer in adults who have had crizotinib.

  13. The Prosigna gene expression profiling assay for assessing long‑term risk of breast cancer recurrence (MIB27)

    This advice has been updated and replaced by NICE diagnostics guidance 34.

  14. Pre-hospital initiation of fluid replacement therapy in trauma (TA74)

    Evidence-based recommendations on giving intravenous (IV) fluid replacement therapy for people with serious injuries before reaching hospital.

  15. Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma (TA321)

    Evidence-based recommendations on dabrafenib (Tafinlar) for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation.

  16. Endoscopic stapling of pharyngeal pouch (IPG22)

    Evidence-based recommendations on endoscopic stapling of pharyngeal pouch. This involves stapling the opening of the pharyngeal pouch through a specially designed endoscope.

  17. Topical antimicrobial dressings for locally infected leg ulcers: late-stage assessment (HTG751)

    Late stage assessment (LSA) guidance on topical antimicrobial dressings for locally infected leg ulcers.

  18. Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)

    Evidence-based recommendations on dapagliflozin (Forxiga) for symptomatic chronic heart failure with reduced ejection fraction in adults.

  19. Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatments (TA1091)

    Evidence-based recommendations on tarlatamab (IMDYLLTRA) for treating extensive-stage small-cell lung cancer after 2 or more treatments in adults.

  20. Endoscopic carbon dioxide laser cricopharyngeal myotomy for relief of oropharyngeal dysphagia (IPG550)

    Evidence-based recommendations on endoscopic carbon dioxide laser cricopharyngeal myotomy for relief of oropharyngeal dysphagia in adults. This involves inserting an endoscope (a thin, rigid tube with a camera on the end) through the mouth, and using a carbon dioxide laser to cut through the muscle that runs round the top of the gullet.

  21. Safe midwifery staffing for maternity settings (NG4)

    This guideline covers safe midwifery staffing in all maternity settings, including at home, in the community, in day assessment units, in obstetric units, and in units led by midwives (both alongside hospitals and free-standing). It aims to improve maternity care by giving advice on monitoring staffing levels and actions to take if there are not enough midwives to meet the needs of women and babies in the service.

  22. Ultrasound-guided regional nerve block (IPG285)

    Evidence-based recommendations on ultrasound-guided regional nerve block. This involves using ultrasound guidance to position needles that deliver local anaesthetic in the correct place next to the nerves.

  23. Vagus nerve stimulation for refractory epilepsy in children (IPG50)

    Evidence-based recommendations on vagus nerve stimulation for refractory epilepsy in children. This involves placing a device under the skin to send a burst of nerve messages through the nerve.

  24. Medical technologies evaluation programme methods guide (PMG33)

    This methods guide describes how NICE selects medical technologies for development of NICE guidance. It also describes how the medical technologies advisory committee develops guidance on selected technologies routed to it

  25. MRI-based technologies for assessing non-alcoholic fatty liver disease (HTG655)

    Evidence-based recommendations on MRI-based technologies for assessing non-alcoholic fatty liver disease.

  26. ColonFlag for identifying people at risk of colorectal cancer (MIB142)

    NICE has developed a medtech innovation briefing (MIB) on ColonFlag for identifying people at risk of colorectal cancer .

  27. Sutureless aortic valve replacement for aortic stenosis (IPG624)

    Evidence-based recommendations on sutureless aortic valve replacement for aortic stenosis in adults. This involves removing the narrowed aortic valve and replacing it with an artificial valve that holds itself in place.

  28. Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy (TA850)

    Evidence-based recommendations on amivantamab (Rybrevant) for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy in adults.

  29. Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (TA307)

    Evidence-based recommendations on aflibercept (Zaltrap) with irinotecan and fluorouracil-based therapy (FOLFIRI) for treating metastatic colorectal cancer after oxaliplatin-based chemotherapy in adults.

  30. Compression products for treating venous leg ulcers: late-stage assessment (HTG758)

    Late-stage assessment (LSA) guidance on compression products for treating venous leg ulcers.

  31. What factors are necessary for an effective and cost effective community-wide approach to obesity prevention?

    existing obesity prevention programmes to support a whole community, in terms of: - geographic coverage - variety of contexts - number...

  32. Lumasiran for treating primary hyperoxaluria type 1 (HST25)

    Evidence-based recommendations on lumasiran (Oxlumo) for primary hyperoxaluria type 1 in people of all ages.

  33. Functional electrical stimulation for drop foot of central neurological origin (IPG278)

    Evidence-based recommendations on functional electrical stimulation for drop foot of central neurological origin. This involves stimulating the peripheral nerves that supply the paralysed muscle using electrodes to restore muscular function.

  34. Managing glioma: management of IDH wildtype grade II glioma:- Does the addition of concurrent and adjuvant temozolomide to radiotherapy improve overall survival in patients with IDH wildtype grade II glioma?

    establish whether or not this approach is beneficial in terms of improved survival, and at what cost in terms of toxicity...

  35. CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic (MIB219)

    NICE has developed a medtech innovation briefing (MIB) on CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic .

  36. eazyplex SuperBug kits for detecting carbapenemase-producing organisms (MIB94)

    NICE has developed a medtech innovation briefing (MIB) on eazyplex SuperBug kits for detecting carbapenemase-producing organisms .

  37. Digital front door technologies to gather service user information for NHS Talking Therapies for anxiety and depression assessments: early value assessment (HTG756)

    Early value assessment (EVA) guidance on digital front door technologies to gather service user information for NHS Talking Therapies for anxiety and depression assessments.

  38. TactiCath Quartz catheter for percutaneous radiofrequency ablation in atrial fibrillation (MIB60)

    NICE has developed a medtech innovation briefing (MIB) on the TactiCath Quartz catheter for percutaneous radiofrequency ablation in atrial fibrillation

  39. Lead-I ECG devices for detecting symptomatic atrial fibrillation using single time point testing in primary care (HTG508)

    Evidence-based recommendations on lead-I electrocardiogram (ECG) devices (imPulse, Kardia Mobile, MyDiagnostick and Zenicor-ECG) for detecting symptomatic atrial fibrillation using single time point testing in primary care.

  40. Neuropad for detecting preclinical diabetic peripheral neuropathy (HTG486)

    Evidence-based recommendations on Neuropad for detecting preclinical diabetic peripheral neuropathy.

  41. PROPATEN heparin-bonded vascular graft for peripheral arterial disease (MIB42)

    NICE has developed a medtech innovation briefing (MIB) on the PROPATEN heparin-bonded vascular graft for peripheral arterial disease

  42. ImmunoCAP ISAC 112 for multiplex allergen testing (HTG413)

    Evidence-based recommendations on multiplex allergen testing, using ImmunoCAP ISAC 112 in people with allergy that is difficult to diagnose.

  43. Laparoscopic ventral mesh rectopexy for internal rectal prolapse (IPG618)

    Evidence-based recommendations on laparoscopic ventral mesh rectopexy for internal rectal prolapse in adults. This involves using a piece of sterile material (mesh) to attach the rectum to the lower back bone using keyhole surgery.

  44. Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver (IPG691)

    Evidence-based recommendations on melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver. This involves diverting the blood flow from the liver to the rest of the body while the drug is delivered directly into the liver.

  45. Artificial intelligence for analysing CT brain scans (MIB207)

    NICE has developed a medtech innovation briefing (MIB) on artificial intelligence for analysing CT brain scans .

  46. Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema (MIB144)

    NICE has developed a medtech innovation briefing (MIB) on Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema .

  47. Feeding interventions for the management of neonatal weight loss:- What is the effectiveness of feeding interventions compared with usual care/advice for breastfedneonates (up to 28 days old) with weight loss of greater than 10%?

    potential for cessation of exclusive breastfeeding with its associated long-term health benefits.Practice varies across the UK. Robust...

  48. Ozanimod for treating relapsing–remitting multiple sclerosis (TA706)

    Evidence-based recommendations on ozanimod (Zeposia) for treating relapsing–remitting multiple sclerosis in adults with clinical or imaging features of active disease.

  49. Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (TA212)

    Evidence-based recommendations on bevacizumab (Avastin), with other drugs, for treating metastatic colorectal cancer in adults.